Tiu C, Yau W, Silva D, Waldron N, et al. Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma. Clin Cancer Res 2026 Apr 27. doi: 10.1158/1078-0432.CCR-25-4364.
PMID: 42043781